Vera Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marshall Fordyce
- Full Time Employees
- 249
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8000 Marina Boulevard Brisbane CA United States of America 94005
- IPO Date
- May 14, 2021
- CIK
- 0001831828
- Website
- veratx.com
- Similar Companies
- Business
- Vera Therapeutics, Inc. (Nasdaq: VERA) is a clinical-stage biotechnology company focused on developing and commercializing transformative biologic treatments for patients with serious immunological and rare diseases, including immunoglobulin A nephropathy (IgAN) and BK virus (BKV) infections. The company's lead product candidate is atacicept, a fully humanized TACI-Fc fusion protein that inhibits B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) to reduce autoantibody production; self-administered at home via weekly subcutaneous injection, atacicept is in late-stage development for IgAN, a progressive kidney disease, with the ORIGIN Phase 3 trial meeting its primary endpoint in June 2025. Vera also advances MAU868, a human monoclonal antibody that neutralizes BKV by blocking host cell binding for treatment of BK viremia in kidney transplant patients; and VT-109, a next-generation BAFF/APRIL dual-inhibitor under exclusive license from Stanford University with potential across B-cell mediated autoimmune diseases. Founded in 2016 and headquartered in Brisbane, California, Vera Therapeutics operates globally with full worldwide rights to its pipeline assets and targets patients with unmet needs in autoimmune kidney disorders and transplant-related complications. Recent milestones include submission of a Biologics License Application (BLA) to the U.S. FDA for atacicept in IgAN in November 2025, positioning the company for potential commercial launch in 2026; expansion of the atacicept program into additional autoimmune diseases such as lupus nephritis; receipt of FDA Breakthrough Therapy Designation in 2024; and maintenance of a strong cash position exceeding $497 million as of September 30, 2025 to support ongoing development.
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
US FDA approves Vera's kidney disease drug
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
What's Going on with Vera Therapeutics Stock on Monday?
3 Biotech Firms With Major Potential Catalysts in the Coming Months
3 Biotech Firms With Major Potential Catalysts in the Coming Months
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)